Top Markets
Coin of the day
Idogen AB (publ) Idogen AB (publ)

Idogen AB (publ)

IDOGEN
Rank in Stocks #37811
Idogen AB (publ) is a Swedish biotechnology company specializing in the... Idogen AB (publ) is a Swedish biotechnology company specializing in the development of tolerogenic cell therapies. These innovative treatments are engineered to prevent a patient's immune system from attacking crucial elements, including biological agents, transplanted organs, and the body's own cells or tissues. The company's most advanced product in development is IDO 8, designed for individuals with severe haemophilia A who have developed neutralizing antibodies against their vital coagulation factor VIII treatment. Idogen is also developing IDO T, a tolerogenic cell therapy intended to prevent organ transplant rejection, primarily for kidney transplants, and IDO AID, aimed at treating autoimmune diseases. Established in 2008, the company is headquartered in Lund, Sweden.
Share Price
$0.01345907
Last synced: 2024-07-12
Market Cap
$1.43M
Change (1 day)
22.16%
Change (1 year)
0.00%
Country
SE
Trade Idogen AB (publ) (IDOGEN)

Category

P/B ratio for Idogen AB (publ) (IDOGEN)
P/B ratio as of 2026 TTM: 0
According to Idogen AB (publ) latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Idogen AB (publ) from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE